Satellos (NASDAQ: MSLE) to present new SAT-3247 Duchenne data at ICNMD 2026
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Satellos Bioscience Inc., a clinical-stage biotechnology company, reported that it will present new data from its SAT-3247 clinical development program at the 19th International Congress on Neuromuscular Diseases in Florence, Italy from July 7–11, 2026. The company will share six-month follow-up results from participants who completed its Phase 1b SAT-3247-CL-101 trial and entered the ongoing Phase 2 TRAILHEAD (LT-001) study, and will also give a Showcase Theatre presentation.
SAT-3247 is an investigational, orally administered small molecule designed to enhance muscle repair and regeneration in Duchenne muscular dystrophy and other degenerative muscle diseases by targeting AAK1. It is being evaluated in two Phase 2 trials, BASECAMP in pediatric patients and TRAILHEAD in adults, and is not yet approved by any health authority.
Positive
- None.
Negative
- None.
Key Figures
ICNMD 2026 dates: July 7–11, 2026
Poster session time: 10:30–11:15 a.m.
Showcase presentation time: 4:05–4:20 p.m.
3 metrics
ICNMD 2026 dates
July 7–11, 2026
19th International Congress on Neuromuscular Diseases in Florence, Italy
Poster session time
10:30–11:15 a.m.
LT-001 long-term follow-up poster on July 8, 2026
Showcase presentation time
4:05–4:20 p.m.
Showcase Theatre talk on July 8, 2026
Key Terms
Phase 1b, Phase 2, Duchenne muscular dystrophy, AAK1, +1 more
5 terms
Phase 1b medical
"six-month follow-up data from participants who completed the Phase 1b SAT-3247-CL-101 trial"
"Phase 1b" is an early stage in testing a new medical treatment or vaccine, where it is given to a small group of people to evaluate its safety and determine the right dose. For investors, this phase signals progress in development, indicating the treatment is advancing through initial safety checks, which can influence expectations for future success and potential market impact.
Phase 2 medical
"with ongoing Phase 2 clinical studies, including TRAILHEAD, an open-label study in adult participants, and BASECAMP"
Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.
Duchenne muscular dystrophy medical
"regenerating skeletal muscle lost in Duchenne muscular dystrophy (DMD) and other degenerative muscle diseases"
A rare, inherited condition that progressively weakens muscles, Duchenne muscular dystrophy causes the body’s muscle fibers to break down over time, often leading to severe disability. For investors, it matters because the small, well-defined patient population, high unmet medical need and complex regulatory and pricing dynamics mean successes or failures in clinical trials, approvals, or therapies can have outsized effects on a company’s valuation and future revenue prospects.
AAK1 medical
"SAT-3247 targets AAK1, a protein that is a key regulator of the body’s natural muscle repair"
AAK1 is a human gene that makes a protein acting like a traffic controller inside cells, helping move and sort molecules into and out of the cell. Investors care because drugs that block or modify AAK1 can change how cells handle infections or neurological signals, so evidence that a therapy affects AAK1 can influence the value of biotech pipelines, clinical trial prospects, and future regulatory or commercial outcomes.
dystrophin-independent medical
"in a dystrophin-independent manner. This mechanistic feature offers SAT-3247 the potential for broad applicability"
FAQ
What did Satellos Bioscience Inc. (MSLE) announce in this 6-K filing?
Satellos announced it will present new SAT-3247 clinical program data at ICNMD 2026. The updates include six-month follow-up results from a Phase 1b trial and information from the ongoing Phase 2 TRAILHEAD study in degenerative muscle diseases.
What is SAT-3247 in Satellos Bioscience’s clinical pipeline?
SAT-3247 is an investigational oral small molecule drug candidate targeting degenerative muscle diseases, including Duchenne muscular dystrophy. It aims to enhance the body’s natural muscle repair and regeneration by inhibiting AAK1, a regulator Satellos identified as disrupted in Duchenne and related conditions.
Which clinical trials of SAT-3247 will be highlighted by Satellos (MSLE)?
Satellos will highlight six-month follow-up data from participants in the Phase 1b SAT-3247-CL-101 trial who enrolled in the Phase 2 TRAILHEAD (LT-001) study. SAT-3247 is also being studied in BASECAMP, a global randomized, placebo-controlled Phase 2 trial in pediatric participants.
When and where will Satellos present SAT-3247 data at ICNMD 2026?
Satellos will present at ICNMD 2026 in Florence, Italy from July 7–11, 2026. A poster session and a Showcase Theatre talk featuring SAT-3247 data are scheduled on Wednesday, July 8, 2026, during morning and afternoon sessions, respectively.
Is SAT-3247 approved for use in patients with Duchenne muscular dystrophy?
SAT-3247 is not yet approved by any health authority. It remains an investigational therapy in Phase 2 clinical trials, being evaluated as a potential disease-modifying, dystrophin-independent treatment approach for Duchenne muscular dystrophy and other degenerative muscle diseases.
How does Satellos describe the mechanism of action of SAT-3247?
Satellos states that SAT-3247 inhibits AAK1, a protein regulating muscle repair and regeneration biology. By inhibiting AAK1, the drug candidate is designed to restore a critical biochemical signal for muscle repair in a dystrophin-independent manner, potentially allowing broad therapeutic applicability.